Bibliographic Details
| Title: |
Te Ara Waiora–Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial |
| Authors: |
Melanie Gibson-Helm, Tania Slater, Evelyn J. MacDonald, Kendall Stevenson, Anna Adcock, Stacie Geller, Varsha Parag, Charles Lambert, Matthew Bennett, Merilyn Hibma, Peter Sykes, Marion Saville, David Hawkes, Jo-Ann Stanton, Mary-Ann Clueard, Grahame Jelley, Bev Lawton |
| Source: |
PLoS ONE, Vol 18, Iss 3 (2023) |
| Publisher Information: |
Public Library of Science (PLoS), 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Medicine
LCC:Science |
| Subject Terms: |
Medicine, Science |
| More Details: |
Background Cervical cancer is caused by high-risk types of human papillomavirus (HPV). Testing for high-risk HPV is a more sensitive screening method than cervical cytology for detecting cervical changes that may lead to cancer. Consistent with recent evidence of efficacy and acceptability, Aotearoa New Zealand plans to introduce HPV testing as the primary approach to screening, replacing cervical cytology, from mid-2023. Any equitable cervical screening programme must be effective across a diverse population, including women that the current programme fails to reach, particularly Māori and those in rural areas. Currently, we do not know the best model for implementing an equitable HPV self-testing screening programme. Methods This implementation trial aims to assess whether a universal offer of HPV self-testing (offered to all people eligible for cervical screening) achieves non-inferior screening coverage (equal) to a universal offer of cervical cytology alone (the present programme). The study population is all people aged from 24.5 to 70 years due for cervical screening in a 12-month period (including those whose screening is overdue or who have never had screening). A range of quantitative and qualitative secondary outcomes will be explored, including barriers and facilitators across screening and diagnostic pathways. This study takes place in Te Tai Tokerau/Northland which covers a diverse range of urban and rural areas and has a large Indigenous Māori population. A total of fourteen practices will be involved. Seven practices will offer HPV self-testing universally to approximately 2800 women and will be compared to seven practices providing routine clinical care (offer of cervical cytology) to an approximately equal number of women. Discussion This trial will answer important questions about how to implement an equitable, high-quality, effective national programme offering HPV self-testing as the primary screening method for cervical cancer prevention. Trial registration Prospectively registered with the Australian New Zealand Clinical Trials Registry 07/12/2021: ACTRN12621001675819. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1932-6203 |
| Relation: |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035917/?tool=EBI; https://doaj.org/toc/1932-6203 |
| Access URL: |
https://doaj.org/article/c580a5653f3f4c85957d8ef1bd2ea8ba |
| Accession Number: |
edsdoj.580a5653f3f4c85957d8ef1bd2ea8ba |
| Database: |
Directory of Open Access Journals |
